Prevymis (Letermovir) Patent Expiration, LOE Window & CMS Spending
Prevymis (Letermovir) by Merck & Co.: FDA Orange Book core substance LOE 2029-01-18 (last listed 2031-08-30), 0 AB generics, $154.7M 2024 CMS Part D & Medicaid spend, and $2,058 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N209939 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2029-01-18 |
| Last Listed Patent or Exclusivity Date | 2031-08-30 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $154.7M |
| 2024 Medicare Part D Spend | $120.5M |
| 2024 Medicaid Spend | $34.2M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($2,058 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.